Reports Q3 revenue $213M, consensus $210.73M. “During the third quarter of 2024, we grew revenue by 11%, compared to the third quarter of ...

Myriad Genetics Inc (MYGN) reports robust revenue growth and strategic initiatives despite facing policy changes impacting ...

Investigation Details On October 31, 2024, it was revealed that UnitedHealth Group (“UnitedHealth”) would no longer cover GeneSight, Myriad’s genetic test to help determine which mental health ...

Global Breast Cancer Screening Tests Market was valued at approximately USD 2.93 billion in 2023 and is projected to grow with a healthy CAGR of 54.3% over the forecast period 2024-2032. Read the ...

Global Cardiovascular Genetic Testing Market is valued at approximately USD 9.07 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 11.2% over the forecast period ...

Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy.

SALT LAKE CITY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, was ...

The catalogue of genetic factors that have been implicated in kidney disease continues to grow. In this guide to gene–disease relationships, the authors discuss the crucial process whereby ...

Myriad Genetics stock was down 21%, to $17.30, in midday Friday trading. Shares of the diagnostic-test maker have fallen 34% over the past month. Starting Jan. 1, the UnitedHealth Group unit plans to ...

Myriad Genetics stock plunges after UnitedHealth Group announces they will no longer cover genetic tests for mental health ...

Out of the 30 companies tracked by 360Dx, 22 saw their share prices decline, seven saw their stock prices increase, and one company’s shares remained essentially flat.